SUP - NIH HEAL Initiative Research Supplements to Promote Diversity

SUP*

SUP - NIH HEAL Initiative Research Supplements to Promote Diversity

Notice Number: NOT-NS-20-107

Key Dates
Release Date: October 19, 2020

Related Announcements
PA-20-222

Purpose

The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-222 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

PA-20-222 is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. However, applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

All instructions in the SF424 (R&R) Application Guide and PA-20-222 must be followed, with the following additions:

  • Application Due Date(s) – November 15, 2020, February 15, 2021, May 15, 2021, November 15, 2021, February 15, 2022, May 15, 2022, November 15, 2022, February 15, 2023, May 15, 2023, November 15, 2023, February 15, 2024, and May 15, 2024 by 5:00 PM local time of applicant organization.

  • For funding consideration, applicants should include “NOT-NS-20-107” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B may not be considered for this initiative.

  • For application guidance, consultation with the Program Official for the qualifying HEAL award and one of those named under Inquiries below is highly recommended.

  • The Research Strategy section of the application is limited to 6 pages.

  • Only existing awards funded or supplemented by the HEAL Initiative are eligible for diversity supplements under this NOSI.

  • To facilitate processing of the supplement application, as the first sentence of the Research Strategy, applicants are requested to state that either:

    • the parent award was funded under the HEAL Initiative and to identify the specific FOA of the parent award (e.g., RFA-NS-20-011, RFA-DA-19-019, etc.); or

    • the parent award has an administrative supplement funded under the HEAL Initiative and to identify the specific notice number of the administrative supplement (e.g., NOT-DA-19-003)

  • Individuals supported by HEAL diversity supplements are strongly encouraged to participate in annual HEAL Initiative PD/PI meetings and in other professional development activities with their mentors. Applicants may request funds in addition to the research costs specified in PA-20-222 to enable the supplement candidate to attend the annual HEAL Initiative PD/PI meeting in the Washington, DC area. This request for additional funds should be reasonable and well justified in the application.
  • When an application has been submitted in response to this NOSI initiative, applicants are strongly encouraged to notify the Program Official for the qualifying HEAL award as well as those named under Inquiries below to facilitate efficient processing of the application.

Supplement applications will be evaluated by the HEAL Initiative diversity committee, made up of program staff from multiple HEAL Institutes and Centers.

Applications non-responsive to the terms of this NOSI will be not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to:

Eric M. Hudak, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: eric.hudak@nih.gov

Michele L. Rankin, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-3832
Email: rankinm@mail.nih.gov

Alexander H. Tuttle, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: alex.tuttle@nih.gov